Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05568420 | RECRUITING | Colorectal Cancer

A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Sponsor:

Memorial Sloan Kettering Cancer Center

Brief Summary:

This study will collect biospecimens (including blood, tissue, and stool samples) and health information to create a database-a type of collection of information-for better understanding young onset colorectal cancer (YOCRC). The study will include both people with YOCRC and healthy people.

Condition or disease

Colorectal Cancer

Study Type : OBSERVATIONAL
Estimated Enrollment : 160 participants
Official Title : Investigation of the Potential Effects of Pharmacologic Agents on Young Onset- Colorectal Cancer
Actual Study Start Date : 2022-09-30
Estimated Primary Completion Date : 2025-09
Estimated Study Completion Date : 2025-09

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 49 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: 1
Criteria
Inclusion Criteria
  • CRC Cohort
    • * 18-49 years old
    • * Histological or cytological diagnosis of colorectal adenocarcinoma
    • * Planned CRC resection biopsy, or colonoscopy ,including surveillance colonoscopies and/or have already undergone prior surgical resection, with tissue, including normal colonic mucosae distant from the malignant tumor (only patients providing tissue sample)
    • * Enrollment in IRB# 20-315, Young Onset Gastrointestinal Cancer Prospective Registry (Andrea Cercek, PI)
    • Healthy Control Cohort
      • * 18-49 years old at time of diagnosis
      • * Scheduled for standard-of-care colonoscopy at MSK
      • * Underwent surgical resection of a traumatic injury to the colon at Shaare Zedek Medical Center (SZMC)
      Exclusion Criteria
      • * CRC Cohort:
      • * Antibiotic use within 6 months of collection of stool for gut microbiome analysis s (only patients providing stool sample)
      • * Known inherited cancer susceptibility gene
      • * History of inflammatory bowel disease
      • Healthy Control Cohort
        • * Antibiotic use within 6 months of collection of stool for gut microbiome analysis (only patients providing stool sample)
        • * History of or prior treatment for cancer ≤ 5 years prior to registration. Exceptions include non-melanoma skin cancer, ductal carcinoma in situ, bladder carcinoma in situ, or carcinoma-in-situ of the cervix.
        • * Colonoscopy for indications of IBD, anemia and/or genetic predisposition (only patients providing tissue sample).
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)

Location Details

NCT05568420

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, New York

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065